Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.
Lenchner DS et al.
Npj Precision Oncology, 2024
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S2
Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report.
Wang R et al.
Oncotargets and Therapy, 2020
Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report.
Yang Y et al.
Frontiers in Oncology, 2020
Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
Qin J et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Select a paper to view details